Let AI watch the worldβs key changes for you unkAI
unkAI continuously tracks the public intelligence and global changes you care about, and only alerts you when noteworthy new developments emerge. Subscribe for free by email β no repeated interruptions, no missed key changes.
Health
72 items Β· Recommended
Progress of China's innovative drugs' overseas commercialization
Track the approval progress, sales revenue growth, changes in overseas revenue proportion of Chinese innovative drugs in European and American markets, as well as the implementation of BD transactions.
Global GLP-1 Drug Market Competition and Sales Changes
Follow up on approval of new indications, entry of new players, price changes, as well as trends in market penetration and sales share changes across different regions.
When will the U.S. FDA approve the new drug Anforglipron?
Follow up on whether FDA's approval result has been announced, confirm whether Anforglipron can become the first once-daily GLP-1 weight loss drug, as well as changes to its launch timing and pricing arrangements.
When will Eli Lilly's new-generation GLP-1 drug be approved for launch?
Focus on Phase III clinical results, FDA approval progress, final approval outcome, launch schedule and pricing strategy announcement.
Global development trends of AI-driven biomarker detection
Follow up on the application progress of AI technology in disease prediction and biomarker detection, and pay attention to accuracy improvement and changes in clinical approval.
Progress of the U.S. FDA's new drug approval reform
Follow up on FDA's reform that allows new drugs to be approved with only one clinical trial, focusing on the implementation time of the rule, adjustment of application scope and changes in industry feedback.
When will the personalized gene editing clinical trials for children with rare genetic diseases be launched?
Follow up on two personalized CRISPR gene editing therapy clinical trials for children with rare genetic diseases, focusing on launch time, patient recruitment progress and safety data disclosure.
Progress of global clinical trials of gene editing therapies
Track the clinical trial progress of personalized gene therapies for rare genetic diseases in 2026, and pay attention to data readout, review promotion and changes in approval possibilities.
Progress of AI-designed proteins entering drug pipelines
Follow up on the follow-up clinical trial promotion and drug research and development progress after Anthropic Claude Mythos model independently designed proteins entered real drug pipelines.
U.S. FDA Innovative Drug Approval Milestones for the Second Half of 2026
Follow up on the review progress, approval results, and new indication expansions of new molecular entity drugs pending FDA review in the second half of the year, and update the annual approved drug list.
Expansion of clinical application of the global innovative hypertension drug baxdrostat
Follow up on clinical application data, indication expansion applications, pharmaceutical company capacity supply and global marketing dynamics after FDA approves baxdrostat for marketing.
Global Research and Development and Clinical Trends of Opioid-Free Analgesics
Track the R&D pipeline of targeted sodium channel opioid-free analgesics, follow up on clinical stage advancement, clinical trial data, pharmaceutical company cooperation and changes in regulatory review nodes.